Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-03-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于公司取得《药品GMP证书》的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (577 characters) from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. about receiving a Drug GMP Certificate issued by the Anhui Provincial Drug Administration. It contains no financial data, no mention of financial results, no shareholder voting, no management changes, no earnings, no legal proceedings, or other financial report content. It is a regulatory compliance announcement related to certification, not a financial or governance report. The document is brief and serves as a formal public notice of certification receipt. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-03-01 Chinese
2018年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2018 年度业绩快报' which translates to '2018 Annual Performance Express Report' or '2018 Annual Earnings Quick Report'. It contains preliminary financial data for the year 2018, including revenue, profit, net income, and other key financial metrics. The document explicitly states that the data is preliminary, unaudited, and may differ from the final annual report. It also mentions that the final audited data will be disclosed in the 2018 Annual Report. The document length is 2122 characters, which is relatively short and consistent with a brief earnings release or performance summary rather than a full annual report. There is no indication that this is a full audited report or a detailed annual report (10-K). Instead, it is a preliminary earnings announcement or earnings release. Therefore, the most appropriate classification is Earnings Release (ER). FY 2018
2019-02-27 Chinese
关于全资子公司获得药品注册申请受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (793 characters) from Anhui Anke Biological Engineering (Group) Co., Ltd. about its wholly-owned subsidiary receiving acceptance of a drug registration application from the National Medical Products Administration. It describes the clinical trial application acceptance for a new drug formulation. There is no financial data, no detailed report, no meeting materials, no voting results, no management discussion, and no regulatory certification. The document is an official announcement of a regulatory milestone related to drug approval, not a financial or governance report. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-02-12 Chinese
2018年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast (业绩预告) for the fiscal year 2018, issued by Anhui Anke Biological Engineering (Group) Co., Ltd. It provides estimated financial results for the full year 2018, including net profit and explanations for performance changes. The document explicitly states that the data is unaudited and preliminary, and that detailed audited results will be disclosed in the company's 2018 annual report. The document length is short (1122 characters), and it is a forward-looking earnings forecast rather than a full financial report or earnings release. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a period, even though it is a forecast rather than final results. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive audited financial statements. It is not a Report Publication Announcement (RPA) because it contains substantive financial estimates, not just a notice of report availability. Therefore, the best fitting category is Earnings Release (ER). FY 2018
2019-01-30 Chinese
关于获得药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Anhui Anke Biotechnology (Group) Co., Ltd. regarding the receipt of a drug registration approval from the National Medical Products Administration. It details the drug name, registration number, approval details, and market context. The document is short (1706 characters) and is an announcement of a regulatory approval event rather than a financial report or management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a significant company event that does not fit other specific categories.
2019-01-25 Chinese
关于公司限售股份上市流通的提示性公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the lifting of restrictions on certain shares held under an employee stock ownership plan, allowing these shares to become freely tradable on the stock exchange. It details the number of shares affected, the lock-up period expiration, and the date when the shares will be available for trading. The document includes information about shareholding changes related to restricted shares becoming unrestricted, but it does not contain financial statements, earnings data, or management discussion. It is not a report like an Annual Report or Interim Report, nor is it a voting result or a capital change announcement in the sense of new share issuance. Instead, it is a regulatory announcement about the change in status of restricted shares becoming tradable, which fits the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-01-20 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.